Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04069299 · ClinicalTrials.gov registry record
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
A clinical trial of Neuroendocrine Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Active
- Registry status
- 30
- Enrollment target
- 1
- Study location
NCT04069299 is a study of Neuroendocrine Carcinoma that is active but no longer recruiting, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 30 participants, below the 279-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04069299, a study of Neuroendocrine Carcinoma, is active but no longer recruiting, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can be a potential alternative in the future. At this time, radiolabeled somatostatin analogs have not been tested in patients with poorly differentiated neuroendocrine carcinomas, and their efficacy in this disease is not well known Understanding the extent and degree of somatostatin receptor expression is important in order to evaluate the potential of radiolabeled somatostatin analog therapy for treatment of poorly differentiated neuroendocrine carcinomas.
Conditions Studied
Interventions
- DRUG 68Ga-DOTATATE
- DIAGNOSTIC_TEST Positron Emission Tomography (PET) Scan
Study Locations (1)
Florida
- H Lee Moffitt Cancer & Research Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2026-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04069299
The ClinicalTrials.gov registry entry for NCT04069299 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (89% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which 68Ga-DOTATATE is the first listed.
NCT04069299 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04069299 about?
NCT04069299 is a clinical study titled "Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract". The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determination if a radiolabeled somatostatin analog therapy, also referred to as peptide receptor radiotherapy (PRRT), can ...
What is the current status of trial NCT04069299?
This trial is currently active not recruiting. The enrollment target is 30 participants. The study started on 2019-09-25. Estimated completion is 2026-01.
What conditions does trial NCT04069299 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT04069299?
The interventions under investigation include: 68Ga-DOTATATE (DRUG), Positron Emission Tomography (PET) Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04069299?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04069299 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.